Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Korean Journal of Gynecologic Oncology

2002 (v1, n1) to Present ISSN: 1671-8925

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

167

results

page

of 17

1

Cite

Cite

Copy

Share

Share

Copy

Rb pathway alteration and E2F-1 expression in epithelial ovarian cancer.

Sung Hee KIM ; Soo Hyeon MOON ; Su Il SHIN ; Dong Soo SUH ; Man Soo YOON ; Kyung Un CHOI

Korean Journal of Gynecologic Oncology.2007;18(4):299-307.

OBJECTIVE: To evaluate the clinicopathological implications of Rb pathway alteration and E2F-1 expression in Epithelial ovarian cancer using immunohistochemical staining. METHODS: Tissue samples (n=72) were collected after staging operation between 1998 and 2004. RESULTS: In 72 cases, the overall expression of pRb, and E2F-1 were 59.7% (43/72), and 58.3% (42/72), respectively. pRb expression was inversely correlated with stage, histologic grade and mitotic index. E2F-1 expression was correlated with advanced stages, high grade, mitotic index, Ki-67 labeling index (LI). CONCLUSION: We suggest that Rb pathway alteration and E2F-1 expression could play roles as a new prognostic factors in Epithelial ovarian cancer.
Mitotic Index ; Ovarian Neoplasms*

Mitotic Index ; Ovarian Neoplasms*

2

Cite

Cite

Copy

Share

Share

Copy

Development of a therapeutic method in the HPV-related cervical lesion using pH/temperature sensitive polymer spray formulation.

Chan Joo KIM ; Byeong Moon JEONG ; Tae Woo KIM ; Tae Heung KANG ; Kyung Hee NOH ; Myoung Ok KIM ; Zae Young RYOO ; Hy Sook KIM ; Jong Sup PARK

Korean Journal of Gynecologic Oncology.2007;18(4):289-298.

OBJECTIVE: The causal link between oncogenic HPV(Human Papilloma Viruses) and the development of CIN (rvical intraepithelial neoplasia) and cervical cancer are now well established. Several medical therapeutic candidates aimd at the treatment of precancerous lesions and invasive carcinoma of the cervix. The objective of this study was to develop the pH-sensitive chitosan/alginate gels (pH=3.8-4.5) and temperature sensitive multiblock copolymers of PEG/PLA (poly (L-lactic acid)/polyethylene glycol) gels (temperature=37 degrees C) for controlled delivery of the paclitaxel (PTX). We had also evaluated whether PTX entrapped in chitosan/alginate gels or multiblock copolymers of PEG/PLA 1 could inhibit tumor growth in vivo. METHODS: PTX entrapped as microsphere in Chitosan/Alginate Microspheres were obtained using a spray-drying method. PTX-entrapped PEG/PLA gels were prepared by the solvent displacement method. We had prepared the multiblock copolymers of PEG/PLA which has the sol-gel-sol transition temperature at body temperature. The in-vivo efficacy of PTX in chitosan microphere or PTX in PEG/PLA mutiblock copolymer micelle were conducted in HeLa-tumor bearing Balb/c Nu/Nu athymic mice at an equivalent paclitaxel dose of 10 mg/kg with 48 hr interval. The inhibition of tumor growth was evaluated after 8 days of treatment. RESULTS: On 8 days after the transcutaneous treatment of PTX-containing chitosan microphere or PTX in PEG/PLA mutiblock copolymer micelle. significant inhibition in tumor growth was observed in balb/c nu/nu nude mouse carrying xenograft tumors (HeLa cells; HPV-18 positive state). Among these formulations, PTX in PEG/PLA mutiblock copolymer have shown improved therapeutic efficacy as compared to PTX-ivgroup. CONCLUSION: PTX-containing chitosan microphere or PTX in PEG/PLA mutiblock copolymer nanoparticles are a unique pH-sensitive and temperature sensitive drug delivery system. These formulations elicits enhanced efficacy as an effective and minimally invasive treatment in mice bearing human cervical cancer (HeLa Cells) xenograft.
Animals ; Body Temperature ; Cervix Uteri ; Chitosan ; Drug Delivery Systems ; Female ; Gels ; Heterografts ; Human papillomavirus 18 ; Humans ; Mice ; Mice, Nude ; Microspheres ; Nanoparticles ; Paclitaxel ; Papilloma ; Polymers* ; Transition Temperature ; Uterine Cervical Neoplasms

Animals ; Body Temperature ; Cervix Uteri ; Chitosan ; Drug Delivery Systems ; Female ; Gels ; Heterografts ; Human papillomavirus 18 ; Humans ; Mice ; Mice, Nude ; Microspheres ; Nanoparticles ; Paclitaxel ; Papilloma ; Polymers* ; Transition Temperature ; Uterine Cervical Neoplasms

3

Cite

Cite

Copy

Share

Share

Copy

Expression of c-Met in ovarian epithelial tumor.

Bo Seop KIM ; Il Soo PARK ; Yoon Soon LEE ; Tae Bon KOO ; Tae In PARK

Korean Journal of Gynecologic Oncology.2007;18(4):284-288.

OBJECTIVE: This study was performed to evaluate the expression of c-Met in epithelial ovarian carcinoma. METHODS: Paraffin-embedded tissues from 50 epithelial ovarian adenocarcinomas were stained immunohistochemically for c-Met expression. The expression of c-Met was correlated with clinicopathologic parameters including, histologic type, tumor size, and tumor stage. RESULTS: c-Met expression was found in 29 cases (58%) among 50 ovarian cancers. In clinicopathologic study, c-Met expression of epithelial ovarian carcinomas did not show the correlation with clinicopathologic parameters such as histologic type, tumor size and stage. CONCLUSION: c-Met expression might be a potential prognostic marker for patients with advanced stage epithelial ovarian cancers. However, larger population-based studies should be performed to determine the prognostic potential of c-Met expression in advanced ovarian carcinoma.
Adenocarcinoma ; Humans ; Ovarian Neoplasms ; Prognosis

Adenocarcinoma ; Humans ; Ovarian Neoplasms ; Prognosis

4

Cite

Cite

Copy

Share

Share

Copy

Recommendation guideline of Korean Society of Gynecologic Oncology and Colposcopy for quadrivalent human papillomavirus vaccine.

Byoung Gie KIM ; Nak Woo LEE ; Seung Cheol KIM ; Young Tae KIM ; Yong Man KIM ; Chan Joo KIM ; Sang Yoon PARK ; Yong Sang SONG ; Jae Kwan LEE ; Won Chul LEE ; Nam Hoon CHO ; Chi Hum CHO ; Soo Young HUR ; Jong Sup PARK ; Kyu Wan LEE

Korean Journal of Gynecologic Oncology.2007;18(4):259-283.

Genital HPV infection is the most common sexually transmitted infection, but the majority of infections are self-limited. However, persistent infection with high-risk types can cause cervical cancer in women, which is the most common female genital cancer in Korea. In addition, HPV infection is the cause of genital warts and is associated with other anogenital cancers. The HPV vaccine is composed of the HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein in yeast using recombinant DNA technology produces noninfectious virus-like particles (VLP) that resemble HPV virions. The quadrivalent HPV vaccine is a mixture of four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18 combined with an aluminum adjuvant. Clinical trials indicate that the vaccine has high efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 among females who have not already been infected with the respective HPV type. The recommended age for primary vaccination of Korean females is 15-17 years, considering sexual debut and duration of protection of the vaccine. Vaccine can be administered as young as age 9 years. Catch-up vaccination is recommended for females aged 18-26 years who have not been previously vaccinated. Vaccination is not a substitute for routine cervical cancer screening, and vaccinated females should have cervical cancer screening as recommended.
Aluminum ; Capsid Proteins ; Colposcopy* ; Condylomata Acuminata ; DNA, Recombinant ; Female ; Human papillomavirus 6 ; Humans* ; Korea ; Mass Screening ; Uterine Cervical Neoplasms ; Vaccination ; Virion ; Vulvar Neoplasms ; Yeasts

Aluminum ; Capsid Proteins ; Colposcopy* ; Condylomata Acuminata ; DNA, Recombinant ; Female ; Human papillomavirus 6 ; Humans* ; Korea ; Mass Screening ; Uterine Cervical Neoplasms ; Vaccination ; Virion ; Vulvar Neoplasms ; Yeasts

5

Cite

Cite

Copy

Share

Share

Copy

Malignant lymphoma of the uterine cervix treated by neoadjuvant chemotherapy.

Soon Ho HWANG ; Bo Yeon KIM ; Jin Hee PARK ; Kyung Eun LEE ; Min A LEE ; Ki Hwan LEE ; Heung Tae NOH ; Sung Kyong SON

Korean Journal of Gynecologic Oncology.2007;18(2):160-164.

Non-Hodgkin's lymphoma presented as a malignancy of the uterine cervix is exceedingly rare disease and accounts for approximately only 0.12-0.6% of extranodal lymphomas. There is no consensus on the management and prognosis of the disease because of its extreme rarity. Previously, treatment of this disease has been radiation therapy, surgery or chemotherapy either alone or in combination. We present the case of a 45-year-old woman diagnosed with diffuse, large B-cell non-Hodgkin's lymphoma of the uterine cervix. We administered neoadjuvant chemotherapy according to CHOP protocol (cyclophosphamide, adriamycin, vincristine, and prednisone) followed by hysterectomy and bilateral salpingo-oophorectomy. The patient is alive 20 months after the initial diagnosis. We report the case with a brief review of literature.
B-Lymphocytes ; Cervix Uteri* ; Consensus ; Diagnosis ; Doxorubicin ; Drug Therapy* ; Female ; Humans ; Hysterectomy ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Middle Aged ; Prognosis ; Rare Diseases ; Vincristine

B-Lymphocytes ; Cervix Uteri* ; Consensus ; Diagnosis ; Doxorubicin ; Drug Therapy* ; Female ; Humans ; Hysterectomy ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Middle Aged ; Prognosis ; Rare Diseases ; Vincristine

6

Cite

Cite

Copy

Share

Share

Copy

A case of recurrent aggressive angiomyxoma of the vulva in the adolescence.

Joo Yuen RYU ; Mi Sun PARK ; Chang Jae LEE ; Kyung Rak SON

Korean Journal of Gynecologic Oncology.2007;18(2):155-159.

Aggressive angiomyxoma is a rare, locally infiltrative soft tissue tumor that usually arises in the vulvoperitoneal region of young female. Frequent relapses are common. Clinicians should consider the diagnosis of aggressive angiomyxoma when a patient presents with an atypical vulvoperineal mass, because an incorrect diagnosis may lead to repeated surgical procedures. Treatment is wide surgical excision. Medical management with a GnRH agonist and radiation therapy with total dose of 60 Gy may be helpful adjuvant treatment in recurrent aggressive angiomyxoma. We experienced a case of recurrent aggressive angiomyxoma and report it with a brief review of literatures.
Adolescent* ; Diagnosis ; Female ; Gonadotropin-Releasing Hormone ; Humans ; Myxoma* ; Recurrence ; Vulva*

Adolescent* ; Diagnosis ; Female ; Gonadotropin-Releasing Hormone ; Humans ; Myxoma* ; Recurrence ; Vulva*

7

Cite

Cite

Copy

Share

Share

Copy

A case of malignant Brenner tumor developed at an ovary after contralateral oophorectomy.

Jin Hee KIM ; Dong Uk LEE ; Sung Chul PARK ; Mi Jin KIM ; Doo Jin LEE ; Sung Ho LEE

Korean Journal of Gynecologic Oncology.2007;18(2):150-154.

The Brenner tumors of the ovary are uncommon and constitute 1.5-2.5% of all ovarian neoplasms. And their malignant counterparts are rare. Although the first malignant Brenner tumor was described by Von Numers in 1945, only a few malignant Brenner tumors have been reported. The definition and its biologic behavior, and the optimal treatment has not been established. We present a patient who had total abdominal hysterectomy with unilateral salpingooophorectomy due to adenomyosis. The resected ovary had only follicular cysts and the remained ovary was grossly normal . Malignant Brenner tumor developed at the remained ovary 15 years after operation. Operation and adjuvant chemotherapy was applied and patient is alive without evidence of disease. We have experienced a case of malignant Brenner tumor developed at the remained ovary after contralateral oophorectomy with a brief review of literature.
Adenomyosis ; Brenner Tumor* ; Chemotherapy, Adjuvant ; Female ; Follicular Cyst ; Humans ; Hysterectomy ; Ovarian Neoplasms ; Ovariectomy* ; Ovary*

Adenomyosis ; Brenner Tumor* ; Chemotherapy, Adjuvant ; Female ; Follicular Cyst ; Humans ; Hysterectomy ; Ovarian Neoplasms ; Ovariectomy* ; Ovary*

8

Cite

Cite

Copy

Share

Share

Copy

Isolated metastasis to the abdominal wall after treatment of unexpected invasive cervical cancer found at total hysterectomy: a case report.

Eun Kyung PARK ; Ok Kyoung KIM ; Woo Mi SIN

Korean Journal of Gynecologic Oncology.2007;18(2):146-149.

Total abdominal hysterectomy was considered an inadequate treatment method for invasive cervical cancer. Usually the procedure was inadvertently performed on patients who were thought preoperatively to have benign conditions. Survival for patients with gross disease remaining after inappropriate hysterectomy is poor. So, early cancer detection and proper management with precise pretreatment staging is necessary to avoid inadequate hysterectomy, especially in cases of gross residual disease. Cervical cancer typically recurs at the vaginal vault or in the pelvis; however it can recur distantly in the abdomen or lung. Although recurrences have been reported at laparoscopic trocar sites, it is unusual to have recurrence in the abdominal wall after laparotomy. A case of isolated metastasis to the abdominal wall after treatment of unexpected invasive cervical cancer found at total hysterectomy is presented with a brief review of the literature.
Abdomen ; Abdominal Wall* ; Humans ; Hysterectomy* ; Laparotomy ; Lung ; Neoplasm Metastasis* ; Pelvis ; Recurrence ; Surgical Instruments ; Uterine Cervical Neoplasms*

Abdomen ; Abdominal Wall* ; Humans ; Hysterectomy* ; Laparotomy ; Lung ; Neoplasm Metastasis* ; Pelvis ; Recurrence ; Surgical Instruments ; Uterine Cervical Neoplasms*

9

Cite

Cite

Copy

Share

Share

Copy

Promoter hypermethylation and loss of heterozygosity of FHIT genes in squamous cell carcinoma of uterine cervix.

Ok Jin KO ; Chel Hun CHOI ; Tae Joong KIM ; Woo Young KIM ; Kyung Mee LEE ; Jung Joo CHOI ; Jeong Won LEE ; Byoung Gie KIM ; Je Ho LEE ; Duk Soo BAE

Korean Journal of Gynecologic Oncology.2007;18(2):139-145.

OBJECTIVE: This study was to investigate the status of hypermethylation and loss of heterozygosity (LOH) in chromosome 3p tumor-suppressor gene for cervical carcinoma. METHODS: We examined the promoter methylation status of the chromosome 3p gene, fragile histidine triad (FHIT), in 37 samples of cervical squamous cell carcinoma and corresponding noncancerous tissues using a methylation-specific polymerase chain reaction. We also analyzed the 37 paired samples for LOH at two loci on chromosome 3p. RESULTS: Promoter hypermethylation in FHIT was detected in 24% of tumors, whereas no hypermethylation was detected in the corresponding noncancerous tissues. LOH in the regions of FHIT was observed in 10% of informative cases. There were no correlations between LOH and promoter hypermethylation for the gene. FHIT hypermethylation was associated with small tumors and, when adjusted for tumor size, correlated significantly with more frequent lymph node metastasis. CONCLUSION: Promoter hypermethylation and LOH of FHIT gene may play a role in cervical carcinogenesis. In addition, hypermethylation of FHIT may be associated with the status (aggressiveness) of cervical carcinoma.
Carcinogenesis ; Carcinoma, Squamous Cell* ; Cervix Uteri* ; Female ; Histidine ; Loss of Heterozygosity* ; Lymph Nodes ; Methylation ; Neoplasm Metastasis ; Polymerase Chain Reaction

Carcinogenesis ; Carcinoma, Squamous Cell* ; Cervix Uteri* ; Female ; Histidine ; Loss of Heterozygosity* ; Lymph Nodes ; Methylation ; Neoplasm Metastasis ; Polymerase Chain Reaction

10

Cite

Cite

Copy

Share

Share

Copy

Expression of telomerase RNA and caspase-3 in cervical intraepithelial lesions and invasive carcinoma.

Young Ok KIM ; Chun June LEE

Korean Journal of Gynecologic Oncology.2007;18(2):131-138.

OBJECTIVE: Telomerase is an RNA-dependent DNA polymerase that synthesizes TTAGGG telomeric DNA. It has been detected in a variety of human malignancies, suggesting that it's activity may play a role in the tumorigenic process. Also, maintenance of telomerase activity is associated with increased resistance to apoptosis. Caspase-3 activation has been found to be essential components of the apoptotic pathway. METHODS: To determine whether telomerase is involved in carcinogenesis of uterine cervix and to analyze the relationship between telomerase RNA and caspase-3 expression according to cervical cancer stage, we performed in situ hybridization for telomerase RNA and immunohistochemistry for caspase-3. The materials were 10 normal cervical tissues, 12 low grade intraepithelial lesions (LSIL), 20 high grade intraepithelial lesions (HSIL), 17 microinvasive carcinomas, 19 invasive carcinomas. RESULTS: Telomerase RNA was weakly expressed in a few basal cells of normal squamous epithelium in uterine cervix. But, high expression rate was noted in squamous intraepithelial lesions and invasive carcinoma groups. Expression of telomerase RNA was demonstrated 5 (41.6%) of LSIL, 7 (35.0%) of HSIL, 6 (35.2%) of microinvasive carcinoma, and 11 (57.8%) of invasive carcinoma. Expression of caspase-3 was demonstrated 0% of LSIL, 13 (65.0%) of HSIL, 13 (76.4%) of microinvasive carcinoma, and 7 (36.8%) of invasive carcinoma. Relationship between telomerase RNA and caspase-3 expression according to stage was not seen. Telomerase RNA and caspase-3 expression showed weakly inverse correlation in invasive carcinoma group. Telomerase RNA and caspase-3 expression was not correlated with clinico-pathologic factors, including stage, tumor differentiation, invasion depth, and lymph node metastasis (p>0.05). But, weak correlation between telomerase RNA expression and tumor size was noted (p=0.05). CONCLUSION: These data indicate telomerase might be involved in carcinogenesis of uterine cervix. Distinct relationship between telomerase RNA and caspase-3 was not seen according to stage. Expression of telomerase RNA and caspase-3 had no correlation with clinico-pathologic factors.
Apoptosis ; Carcinogenesis ; Caspase 3* ; Cervix Uteri ; DNA ; Epithelium ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Lymph Nodes ; Neoplasm Metastasis ; RNA* ; RNA-Directed DNA Polymerase ; Telomerase* ; Uterine Cervical Neoplasms

Apoptosis ; Carcinogenesis ; Caspase 3* ; Cervix Uteri ; DNA ; Epithelium ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Lymph Nodes ; Neoplasm Metastasis ; RNA* ; RNA-Directed DNA Polymerase ; Telomerase* ; Uterine Cervical Neoplasms

Country

Republic of Korea

Publisher

Korean Society of Gynecologic Oncology and Colposcopy

ElectronicLinks

http://ejgo.org

Editor-in-chief

E-mail

Abbreviation

Korean J Gynecol Oncol

Vernacular Journal Title

부인종양

ISSN

1738-6543

EISSN

Year Approved

2007

Current Indexing Status

Currently Indexed

Start Year

Description

Current Title

Journal of Gynecologic Oncology

Previous Title

Korean Journal of Gynecologic Oncology and Colposcopy

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.